Home > Newsletters > The QMN Weekly Bulletin > Novartis’ Troubled Lincoln Plant to Stay Sidelined Until 2013: CEO
The QMN Weekly Bulletin
Nov. 9, 2012 | Vol. 4 No. 45
Novartis’ Troubled Lincoln Plant to Stay Sidelined Until 2013: CEO
Slow remediation of GMP problems at Novartis’ Lincoln, Neb., OTC drug plant has dashed hopes for a pre-2013 return to production, company officials say. “We’re making progress but it’s just not fast enough,” Novartis CEO Joe Jimenez said on recent conference call. The company had hoped to begin resupplying customers from Lincoln over the summer but the drugmaker also faces “intense remediation” at three North American facilities operated by its Sandoz subsidiary after receiving a warning letter last year.
Drug GMP Report
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.